Everything tagged "medicaid" across the TickerSpark archives.
Molina Healthcare faces a sharp 2026 earnings reset, but Medicaid rate normalization and improving Medicare duals could support a 2027 rebound. The stock looks more like a Hold than a Buy while execution risk remains high.
Centene is showing real margin-recovery progress after a difficult 2025, but Medicaid, Marketplace, and Medicare cost pressure still make this a Hold. Q1 2026 results and raised guidance support the turnaround, though the stock already trades near consensus value.
Elevance didn't get punished for missing the quarter; it got punished because the market no longer trusts the quality of the beat. Raised guidance matters less when Medicaid costs are still rising, membership is slipping, and management is calling 2026 the low point for profitability.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime